The Menarini Group, an international pharmaceutical and diagnostics company, Stemline Therapeutics Inc., a wholly-owned subsidiary of the Menarini Group, and Insilico Medicine, a clinical stage generative artificial intelligence (AI)-driven biotechnology company, have entered into an exclusive licensing agreement granting Stemline the global rights to develop and commercialize a preclinical small molecule targeting high unmet needs in oncology. The asset is a highly selective and potentially ...